Core Viewpoint - The article emphasizes the importance of cancer prevention and the advancements in antibody-drug conjugates (ADCs) as a promising treatment for lung cancer, particularly focusing on the B7H3 target in clinical trials [2][3][7]. Group 1: Cancer Prevention and Awareness - The 31st National Cancer Prevention Week aims to promote scientific knowledge about cancer prevention and encourage healthy lifestyles to control cancer risk factors [1]. - The campaign encourages high-risk individuals to participate in cancer screenings and emphasizes the importance of early diagnosis and treatment [1]. Group 2: Lung Cancer Statistics - Lung cancer is the most prevalent and deadly malignancy in China, with approximately 870,000 new cases and over 760,000 deaths reported in 2022, accounting for nearly 40% of the global lung cancer burden [2]. - Non-small cell lung cancer (NSCLC) constitutes 80%-85% of lung cancer cases, while small cell lung cancer (SCLC) represents 15% but has a very poor prognosis with a 5-year survival rate of less than 7% [2]. Group 3: Advancements in ADCs - Antibody-drug conjugates (ADCs) are emerging as a new treatment paradigm, combining the precision of targeted therapy with the potency of chemotherapy, referred to as "Chemotherapy 2.0" [2][6]. - Over a dozen ADCs have been approved globally, with six major ADCs expected to be approved by 2025, targeting key markers such as HER2, TROP2, and B7H3 [2]. Group 4: Clinical Research and Breakthroughs - The clinical study of the B7H3-targeted ADC YL201 shows objective response rates of 48.6% for nasopharyngeal cancer and 63.9% for small cell lung cancer, significantly outperforming existing treatments [3][7]. - The research team is conducting two pivotal Phase III clinical trials for small cell lung cancer and nasopharyngeal cancer, with YL201 already recognized as a breakthrough therapy by national authorities [7][10]. Group 5: Global Positioning and Future Directions - Currently, no B7H3-targeted ADC has been approved globally, placing this research at the forefront of ADC development [8]. - The rapid progression from Phase I to Phase III trials is attributed to encouraging efficacy data and the significant unmet clinical needs in targeted cancers [10]. - The focus on early prevention and diagnosis is highlighted as crucial for reducing cancer incidence, with a call for increased public awareness and lifestyle changes [11].